Bristol Myers Squibb (BMS) has announced a strategic agreement with Anthropic to deploy Claude across the company’s research, clinical development, manufacturing, commercial and corporate functions.
The collaboration signals a meaningful evolution in how the company deploys AI, moving beyond conversational tools that have defined the first wave of enterprise adoption, toward agentic capabilities built into the day-to-day workflows and systems that underpin its science and global operations.
BMS will deploy Claude broadly across the company, empowering more than 30,000 employees with advanced reasoning and agentic capabilities. The deployment focuses on three priorities where BMS expects the highest near-term impact: accelerating engineering with Claude Code, embedding agents into the workflows that move drugs forward and connecting Claude to the institutional knowledge that lives across BMS.
The collaboration builds on more than three years of AI investment at BMS, where the company has given employees unlimited access to leading frontier models through a proprietary internal platform. Those investments have established BMS as a leader in AI integration across research, clinical development, manufacturing and commercial functions, and reflect a deliberate multi-vendor strategy that draws on the best capabilities the industry has to offer.
Greg Meyers, EVP and Chief Digital & Technology Officer at Bristol Myers Squibb, said: “Most enterprise AI stops at the chatbot. The real prize is the untapped value still trapped behind decades of data silos, and this collaboration is how we reach it. Anthropic’s Claude gives us the agentic capabilities, pace of innovation, and security necessary to connect our systems and put that collective knowledge in the hands of every BMS employee to accelerate innovation for patients.”
Eric Kauderer-Abrams, Head of Life Sciences at Anthropic, commented: “By giving employees access to Claude’s agentic capabilities – connected to thousands of data sources across the company – BMS is creating a single intelligence layer that can generate a clinical study report from underlying trial data, surface the right scientific context from decades of internal research, or trace the root cause of a manufacturing deviation in real time. In a regulated global enterprise, that means medicines reach patients faster.”